Locally Advanced or Metastatic Solid Tumors

Oncology
11
Pipeline Programs
10
Companies
11
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

AB
AP BiosciencesTaiwan - Taipei
1 program
1
AP203Phase 1/21 trial
Active Trials
NCT05473156RecruitingEst. Dec 2027
InxMed
InxMedChina - Beijing
1 program
1
IN10018+PLDPhase 1/21 trial
Active Trials
NCT05830539Completed68Est. Nov 2024
CP
Chugai PharmaJapan - Tokyo
2 programs
2
LUNA18Phase 11 trial
SPYK04Phase 11 trial
Active Trials
NCT05012618Terminated128Est. Nov 2025
NCT04511845Active Not Recruiting113Est. Sep 2026
Antengene
AntengeneChina - Shanghai
1 program
1
ATG-037Phase 1
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
DemcizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT02722954Completed29Est. May 2017
BioCity Biopharma
BioCity BiopharmaChina - Wuxi
1 program
1
Drug: BC3195 for InjectionPhase 11 trial
Active Trials
NCT05957471UnknownEst. Jun 2025
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
MK-2206Phase 1
LB
Lepu BiopharmaChina - Shanghai
1 program
1
MRG007Phase 11 trial
Active Trials
NCT07066657RecruitingEst. Dec 2030
M&
Merck & Co.RAHWAY, NJ
1 program
1
PimasertibPhase 1Small Molecule3 trials
Active Trials
NCT01985191Completed26Est. Feb 2016
NCT01713036Completed6Est. Jul 2014
NCT01668017Terminated26Est. May 2015
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
W0180Phase 11 trial
Active Trials
NCT04564417Terminated33Est. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AP BiosciencesAP203
InxMedIN10018+PLD
Lepu BiopharmaMRG007
BioCity BiopharmaDrug: BC3195 for Injection
Chugai PharmaLUNA18
Chugai PharmaSPYK04
Pierre FabreW0180
Mereo BioPharmaDemcizumab
Merck & Co.Pimasertib
Merck & Co.Pimasertib
Merck & Co.Pimasertib

Clinical Trials (11)

Total enrollment: 429 patients across 11 trials

NCT05473156AP BiosciencesAP203

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Start: Jul 2023Est. completion: Dec 2027
Phase 1/2Recruiting
NCT05830539InxMedIN10018+PLD

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Start: Mar 2022Est. completion: Nov 202468 patients
Phase 1/2Completed
NCT07066657Lepu BiopharmaMRG007

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Start: Jul 2025Est. completion: Dec 2030
Phase 1Recruiting
NCT05957471BioCity BiopharmaDrug: BC3195 for Injection

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

Start: Jun 2023Est. completion: Jun 2025
Phase 1Unknown
NCT05012618Chugai PharmaLUNA18

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Start: Oct 2021Est. completion: Nov 2025128 patients
Phase 1Terminated
NCT04511845Chugai PharmaSPYK04

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Start: Sep 2020Est. completion: Sep 2026113 patients
Phase 1Active Not Recruiting
NCT04564417Pierre FabreW0180

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Start: Sep 2020Est. completion: Dec 202333 patients
Phase 1Terminated
NCT02722954Mereo BioPharmaDemcizumab

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

Start: Jan 2016Est. completion: May 201729 patients
Phase 1Completed
NCT01985191Merck & Co.Pimasertib

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

Start: Nov 2013Est. completion: Feb 201626 patients
Phase 1Completed
NCT01713036Merck & Co.Pimasertib

Oral Bioavailability and Mass Balance Trial With Pimasertib

Start: Nov 2012Est. completion: Jul 20146 patients
Phase 1Completed
NCT01668017Merck & Co.Pimasertib

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Start: Sep 2012Est. completion: May 201526 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 429 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)